EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis

Cristina Arriens iD, Y K Onno Teng iD, Ellen M Ginzler, Samir V Parikh, Anca D Askanase iD, Amit Saxena iD, Keisha Gibson iD, Dawn J Caster, Tatsuya Atsumi, Laura Lisk, Simrat Randhawa iD, Rashieda Gluck und 2 weitere

Arthritis Care & Research · 2023-07 · 75 (7) · 1399-1408

DOI: 10.1002/acr.25007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis Care & Research, online erschienen am 12.02.2023. Verfasst von Cristina Arriens und 13 weiteren Autor:innen. Beteiligte Einrichtung: Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Lupus Nephritis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials. The purpose was to expand the pool of patients for safety analyses and to increase power for efficacy analyses in patient subpopulations .

Methods

Aurinia Urinary Protein Reduction in Active Lupus with Voclosporin (AURA‐LV) (phase II) and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA 1) (phase III) were randomized, placebo‐controlled, double‐blind trials with similar designs and end points comparing voclosporin to control in combination with MMF and oral glucocorticoids for the treatment of LN. The primary efficacy outcome of the integrated analysis was complete renal response (CRR) at approximately one year (Week 48 data from AURA‐LV and Week 52 from AURORA 1). Safety was assessed throughout the trials.

Results

Overall, 534 patients (268 voclosporin; 266 control) were included in the integrated analysis. Significantly more patients achieved a CRR at one year in the voclosporin group than in the control group (43.7% vs. 23.3%; OR 2.76; 95% CI 1.88, 4.05 P < 0.0001). The incidence of adverse events (AEs) was similar (91.4% voclosporin; 87.2% control). Most AEs were mild to moderate in severity; the most commonly reported AEs were classified as infections and infestations (62.2% voclosporin; 54.9% control) and gastrointestinal disorders (45.3% voclosporin; 35.3% placebo). No new or unexpected safety signals were detected.

Conclusions

This integrated analysis demonstrates the efficacy and safety of voclosporin in the treatment of LN across the diverse racial and ethnic groups studied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsLupus NephritisHumansGlucocorticoidsMycophenolic AcidTreatment OutcomeClinical Trials as TopicCyclosporine

Substanzen

GlucocorticoidsImmunosuppressive AgentsMycophenolic AcidvoclosporinCyclosporine

Autor:innen und Institutionen

  • Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.
  • Leiden University Medical Centre, Leiden, The Netherlands.
  • SUNY Downstate Health Sciences University, Brooklyn, New York.
  • The Ohio State University Wexner Medical Center, Columbus.
  • Columbia University Lupus Center, New York, New York.
  • New York University School of Medicine, New York.

ORCID-Profile: Cristina Arriens, Y K Onno Teng, Anca D Askanase, Amit Saxena, Keisha Gibson, Simrat Randhawa, Robert B Huizinga

Zitieren

APA

Arriens, C., Teng, Y. K. O., Ginzler, E. M., Parikh, S. V., Askanase, A. D., Saxena, A., Gibson, K., Caster, D. J., Atsumi, T., Lisk, L., Randhawa, S., Gluck, R., Solomons, N., & Huizinga, R. B. (2023). Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care & Research, 75(7), 1399-1408. https://doi.org/10.1002/acr.25007

Vancouver

Arriens C, Teng YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, et al. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care & Research. 2023;75(7):1399-1408. doi:10.1002/acr.25007

BibTeX
@article{Arriens2023,
  author = {Arriens, Cristina and Teng, Y K Onno and Ginzler, Ellen M and Parikh, Samir V and Askanase, Anca D and Saxena, Amit and Gibson, Keisha and Caster, Dawn J and Atsumi, Tatsuya and Lisk, Laura and Randhawa, Simrat and Gluck, Rashieda and Solomons, Neil and Huizinga, Robert B},
  title = {Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis},
  journal = {Arthritis Care & Research},
  year = {2023},
  volume = {75},
  number = {7},
  pages = {1399--1408},
  doi = {10.1002/acr.25007}
}
Kostenlos starten →